By Aveluro Research Team · Editorial policy
AGP (AGP) is a company in Vietnam's Health Care sector, listed on UPCOM. The stock last traded at 31,600 VND, little changed on the session, giving a market capitalization of 1.2 trillion VND.
On valuation, AGP trades at a price-to-earnings ratio of 22.9 and a price-to-book of 2.1. That is broadly in line with the Health Care sector average P/E of 22.2. Return on equity of 9.3% points to modest profitability relative to the company's equity base, below the sector average of 10.4%. Trailing earnings per share stand at 1,465 VND.
Aveluro tracks 1 news item mentioning AGP, where recent coverage skews mixed (100% of articles). The most recent catalyst was an earnings inline event — "Agimexpharm (AGP) reported Q2 net profit up 23% YoY to 15.8 billion VND, but operating cash flow turned deeply negative at -142.5 billion VND due to rising receivables and inventory, while cash dropped 75%.". Aveluro's composite model rates AGP 6.5/10 (Buy), blending news sentiment, price momentum, and fundamentals.
Comparable names in the Health Care sector include AMV, APC and BCP.
What matters now
Agimexpharm (AGP) reported Q2 net profit up 23% YoY to 15.8 billion VND, but operating cash flow turned deeply negative at -142.5 billion VND due to rising receivables and inventory, while cash dropped 75%.
Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.